News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) ...

In an important development for patients with non-alcoholic steatohepatitis (NASH), Madrigal Pharmaceuticals, Inc. (NASDAQ: ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities rose in ...

Review demonstrates curcumin's neuroprotective effects in neurodegenerative diseases, enhancing its potential through ...

Fad weight loss solutions are all the rage, but natural weight loss ingredients backed by science include berberine, curcumin ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a ...

Structure Therapeutics is offering over nine million shares on the heels of mid-stage data for its oral GLP-1 receptor ...

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of ...

The US FDA has approved once-daily Onyda XR as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

Viking Therapeutics ( VKTX 4.71%) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the ...

Analyst Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) and ...

Analyze any exercise, and you’ll find a host of muscles performing different functions or roles. These are: Agonist – also known as the prime mover, this is the muscle doing most of the work and is ...